Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Epithelial-mesenchymal transition in prostate cancer: an overview.

Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, Muscariello R, Berretta M, Perdonà S, Muto P, Botti G, Bianchi AAM, Veneziani BM, Facchini G.

Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686. Review.

2.

Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Malek R, Wang H, Taparra K, Tran PT.

Cells Tissues Organs. 2017;203(2):114-127. doi: 10.1159/000447238. Epub 2017 Feb 20. Review.

3.

Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer.

Yang H, Zhang H, Zhong Y, Wang Q, Yang L, Kang H, Gao X, Yu H, Xie C, Zhou F, Zhou Y.

Sci Rep. 2017 Feb 14;7:41670. doi: 10.1038/srep41670.

4.

Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.

Andrade SS, Sumikawa JT, Castro ED, Batista FP, Paredes-Gamero E, Oliveira LC, Guerra IM, Peres GB, Cavalheiro RP, Juliano L, Nazário AP, Facina G, Tsai SM, Oliva ML, Girão MJ.

Oncotarget. 2017 Mar 7;8(10):16851-16874. doi: 10.18632/oncotarget.15170.

5.

Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling.

Zhang X, Fan Q, Li Y, Yang Z, Yang L, Zong Z, Wang B, Meng X, Li Q, Liu J, Li H.

Oncotarget. 2017 May 2;8(18):29785-29794. doi: 10.18632/oncotarget.14523.

6.

An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.

Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL.

Mol Cell Proteomics. 2017 Feb;16(2):265-277. doi: 10.1074/mcp.M116.058172. Epub 2016 Dec 11.

PMID:
27940637
7.

TGF-β/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression: IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION.

Zhao J, Liu J, Lee JF, Zhang W, Kandouz M, VanHecke GC, Chen S, Ahn YH, Lonardo F, Lee MJ.

J Biol Chem. 2016 Dec 30;291(53):27343-27353. doi: 10.1074/jbc.M116.740084. Epub 2016 Nov 17.

PMID:
27856637
8.

Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.

Kanamoto A, Ninomiya I, Harada S, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Oyama K, Miyashita T, Tajima H, Takamura H, Fushida S, Ohta T.

Int J Oncol. 2016 Nov;49(5):1859-1869. doi: 10.3892/ijo.2016.3712. Epub 2016 Sep 27.

9.

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.

Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL.

Cancer Discov. 2016 Dec;6(12):1366-1381. Epub 2016 Sep 28.

10.

Effects for Sequential Treatment of siAkt and Paclitaxel on Gastric Cancer Cell Lines.

Ku M, Kang M, Suh JS, Yang J.

Int J Med Sci. 2016 Sep 7;13(9):708-16. doi: 10.7150/ijms.15501. eCollection 2016.

11.

Ginsenoside Rd attenuates breast cancer metastasis implicating derepressing microRNA-18a-regulated Smad2 expression.

Wang P, Du X, Xiong M, Cui J, Yang Q, Wang W, Chen Y, Zhang T.

Sci Rep. 2016 Sep 19;6:33709. doi: 10.1038/srep33709.

12.

TGFβ upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.

Smoktunowicz N, Platé M, Stern AO, D'Antongiovanni V, Robinson E, Chudasama V, Caddick S, Scotton CJ, Jarai G, Chambers RC.

Oncotarget. 2016 Oct 4;7(40):65471-65484. doi: 10.18632/oncotarget.11472.

13.

TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways.

Xiong S, Cheng JC, Klausen C, Zhao J, Leung PC.

Oncotarget. 2016 Sep 20;7(38):61262-61272. doi: 10.18632/oncotarget.11311.

14.

Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran.

Parvizi S, Mohammadzadeh G, Karimi M, Noorbehbahani M, Jafary A.

Iran J Cancer Prev. 2016 Feb 24;9(1):e5266. doi: 10.17795/ijcp-5266. eCollection 2016 Feb.

15.

Metformin is a novel suppressor for transforming growth factor (TGF)-β1.

Xiao H, Zhang J, Xu Z, Feng Y, Zhang M, Liu J, Chen R, Shen J, Wu J, Lu Z, Fang X, Li J, Zhang Y.

Sci Rep. 2016 Jun 28;6:28597. doi: 10.1038/srep28597.

16.

Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.

Reiser J, Banerjee A.

J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260. Epub 2016 May 22. Review.

17.

Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer.

Ding MJ, Su KE, Cui GZ, Yang WH, Chen L, Yang M, Liu YQ, Dai DL.

Oncol Lett. 2016 Jun;11(6):4040-4044. Epub 2016 Apr 26.

18.

Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells.

Liu B, Shi Y, Peng W, Zhang Q, Liu J, Chen N, Zhu R.

Mol Med Rep. 2016 Jul;14(1):159-64. doi: 10.3892/mmr.2016.5258. Epub 2016 May 12.

19.

Recombinant fibromodulin has therapeutic effects on diabetic nephropathy by down-regulating transforming growth factor-β1 in streptozotocin-induced diabetic rat model.

Jazi MF, Biglari A, Mazloomzadeh S, Kingston P, Ramazani A, Bazzaz JT, Eskandari M.

Iran J Basic Med Sci. 2016 Mar;19(3):265-71.

20.

Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.

Haxho F, Neufeld RJ, Szewczuk MR.

Oncotarget. 2016 Jun 28;7(26):40860-40881. doi: 10.18632/oncotarget.8396. Review.

Supplemental Content

Support Center